First AD

Second AD

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD  

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host Disease

Insights

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)

Cancer Centers

Partner

AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD

Graft-Versus-Host Disease: Pathogenesis, Clinical Challenges, and Unmet Treatment Needs

The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway

Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD